Interactions on record — worth a quick check against your medications. Check your meds →
Dietary supplement

PureBi-Ome Intensive Ingredients & Drug Interactions

by Pure Encapsulations

Capsule Category: Non-nutrient/non-botanical
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

PureBi-Ome Intensive is a dietary supplement by Pure Encapsulations with 1 active ingredient. Its ingredients are commonly taken for digestive health and balance, diarrhea (including antibiotic-related), vaginal yeast and bacterial infections.Based on those ingredients, 222 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Probiotic Blend. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of PureBi-Ome Intensive by Pure Encapsulations

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Low disclosure
Ingredient Transparency · database check
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 0 of its 5 active ingredients.
  • “Probiotic Blend” is a proprietary blend — the label doesn't break down how much of each component you get.

PureBi-Ome Intensive contains 5 active ingredients: a probiotic blend made up of Saccharomyces boulardii (a beneficial yeast), two different strains of Lactobacillus acidophilus, Bifidobacterium lactis, and Bifidobacterium bifidum. These are live microorganisms meant to support your gut flora.

The capsules also contain vegetarian capsule material, plant fiber, and silica as inactive ingredients.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: support intestinal microbial balance and health.
  • We looked for evidence on: Antibiotic-associated diarrhea, Clostridioides difficile infection, Constipation, Crohn disease, Inflammatory bowel disease (IBD), Intestinal parasite infection — and 4 related terms.
  • The strongest evidence on file: Saccharomyces Boulardii is rated "Possibly Effective" for Antibiotic-associated diarrhea (Natural Medicines).
  • Also on file: Saccharomyces Boulardii is rated "Possibly Effective" for Clostridioides difficile infection.
  • Also on file: Lactobacillus Acidophilus is rated "Possibly Effective" for Antibiotic-associated diarrhea, Irritable bowel syndrome (IBS).

Saccharomyces boulardii is listed as possibly effective for rotaviral diarrhea, travelers' diarrhea, antibiotic-associated diarrhea, necrotizing enterocolitis, Clostridioides difficile infection, and Helicobacter pylori. The Lactobacillus acidophilus strains are possibly effective for irritable bowel syndrome, Helicobacter pylori, antibiotic-associated diarrhea, and bacterial vaginosis, but possibly ineffective for atopic disease; evidence for acute respiratory distress syndrome is insufficient.

Bifidobacterium bifidum is possibly effective for irritable bowel syndrome and respiratory tract infections, with insufficient evidence for allergic rhinitis, Alzheimer disease, and generalized anxiety disorder. We hold no effectiveness data for Bifidobacterium lactis.

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 3 of the 3 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 3 of 3.
  • General safety write-ups exist for 3 of 3.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Saccharomyces boulardii is generally well tolerated in healthy adults but should be avoided by people who are critically ill or immunocompromised; rare cases of fungemia (yeast infection in the bloodstream) have been reported, particularly in ICU patients or those with central catheters. It has rarely caused gastrointestinal complaints like abdominal cramps, flatulence, nausea, vomiting, and decreased appetite.

The Lactobacillus and Bifidobacterium strains are generally well tolerated in healthy adults and children, though uncommon gastrointestinal side effects like abdominal pain, bloating, flatulence, and diarrhea can occur when taking them with other probiotics. Rare cases of serious infection (bacteremia, sepsis, abscess) have been reported with Lactobacillus acidophilus, though these typically occur in people with underlying conditions or catheters.

We hold no pregnancy or lactation safety data for Saccharomyces boulardii; Lactobacillus acidophilus and Bifidobacterium bifidum are rated possibly safe in pregnancy.

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 3 of the 3 matched ingredients can interact with medications — Saccharomyces Boulardii, Lactobacillus Acidophilus, Bifidobacterium Bifidum.
  • The most serious interaction on file is rated Moderate.
  • For scale: 222 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before you start PureBi-Ome Intensive, double-check antibiotic drugs with your doctor or pharmacist — they interact with three of the live bacterial strains at a Moderate level. Also confirm with your healthcare provider if you take any antifungal drugs, which interact with the Saccharomyces boulardii at a Minor level.

The search tool on this page can help you verify your exact medications.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFormula with limited ingredient disclosure with some supporting evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

This product may help with certain types of diarrhea and gut-related conditions if the evidence is strong enough for your situation. If you're on antibiotics or antifungals, spacing out when you take this product matters — talk with your doctor or pharmacist about the best timing.

People who are critically ill, have weak immune systems, or have central catheters should check with their healthcare provider first.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 4 of 5 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Feb 23, 2022.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about PureBi-Ome Intensive, straight from the product label.

Brand Pure Encapsulations
Barcode (UPC) 766298015446
Net contents 30 Capsule(s)
Market status On market
Date entered into DSLD Feb 23, 2022
DSLD ID 261618
Product type Non-nutrient/non-botanical
Supplement form Capsule
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Adult (18 - 50 Years), Gluten Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for PureBi-Ome Intensive by Pure Encapsulations, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Capsule(s)
Maximum serving Sizes:
1 Capsule(s)
Servings per container
30
UPC/BARCODE
766298015446
IngredientAmount% DV
Probiotic Blend0 NP--
Saccharomyces boulardii0 NP--
Lactobacillus acidophilus (NCIMB 30157)0 NP--
Lactobacillus acidophilus (NCIMB 30156)0 NP--
Bifidobacterium lactis (NCIMB 30172)0 NP--
Bifidobacterium bifidum (NCIMB 30153)0 NP--

Other ingredients: Vegetarian Capsule, hypoallergenic Plant Fiber, Silica

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Storage

Keep refrigerated

Suggested/Recommended/Usage/Directions

Recommendations: As a dietary supplement, take 1 capsule daily, with a meal.

Precautions

Warning: Probiotics may be contraindicated for immunocompromised individuals.

If you are pregnant or lactating, have any health condition or are immunocompromised, or are taking medication, consult your health professional before use.

Keep out of the reach of children.

Use only if safety seal is intact.

General Statements

Contents may not fill package in order to accommodate required labeling. Please rely on stated quantity. Scan to learn about our hypoallergenic supplements

Formulation

Probiotic combination to support intestinal microbial balance and health

Gluten-free, non-GMO & Hypoallergenic

Gluten-free, non-GMO & Hypoallergenic

FDA Statement of Identity

Dietary Supplement

FDA Disclaimer Statement

This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

See for yourself

PureBi-Ome Intensive by Pure Encapsulations label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in PureBi-Ome Intensive by Pure Encapsulations

This is the 1 active ingredient this product is made of. Select it to open its full monograph.

Serving size1 Capsule(s) Dosage formCapsule Servings per container30 Amounts shown are per serving.

Probiotic Blend

Interacts with
182 drugs
0 NP per serving

Lactobacillus acidophilus is a 'friendly' bacterium used as a probiotic to support gut and vaginal health. It is generally well tolerated in healthy p...

Probiotic Blend monograph & interactions

Other (inactive) ingredients: Vegetarian Capsule, Hypoallergenic Plant Fiber, Silica. These complete the product’s ingredient list but are not active constituents.

Interaction report

PureBi-Ome Intensive by Pure Encapsulations Drug Interactions

Want to check YOUR meds against PureBi-Ome Intensive?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
222Drugs
182 Moderate 40 Minor

Ingredients driving the most interactions

Each ingredient & the kinds of drugs it affects

For each ingredient in PureBi-Ome Intensive with known interactions, here are the types of medications it can affect. Open any type for the detail — or search your exact drug in the checker above.

Probiotic Blend1 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Lactobacillus acidophilus with antibiotic drugs might decrease the effectiveness of L. acidophilus.
L. acidophilus preparations usually contain live and active organisms. Therefore, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and L. acidophilus preparations by at least two hours.

Likelihood Probable Evidence D
The maker

Brand information

Manufacturer and brand details for PureBi-Ome Intensive, from the product label.

Pure Encapsulations

See all Pure Encapsulations products
Name
Pure Encapsulations
Street Address
490 Boston Post Road
City
Sudbury
State
MA
Phone Number
1-800-753-2277
Web Address
www.PureEncapsulations.com
Pharmacist Counseling Corner

PureBi-Ome Intensive by Pure Encapsulations: Common Questions

Does PureBi-Ome Intensive by Pure Encapsulations interact with any medications?
Yes. Based on its ingredients, PureBi-Ome Intensive has a known interaction with 222 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
PureBi-Ome Intensive contains a single active ingredient, and that one ingredient can interact with many different medications on its own. We check it against each medication and show the mechanism responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
What are the live organisms in this product for?
Probiotics like these are meant to support your gut flora. This blend contains strains that have evidence suggesting they may help with things like irritable bowel syndrome, antibiotic-associated diarrhea, travelers' diarrhea, and certain infections — though not every strain works for every condition.
Can I take this while I'm on antibiotics?
Antibiotics kill the live bacteria and yeast in this product, so it won't work as intended if you take them together. Ask your doctor or pharmacist about spacing them apart — there's usually a window of time you can leave between the two.
Is this safe if I have a weak immune system?
The safety data advises against Saccharomyces boulardii if you're immunocompromised, because rare cases of serious infection have been reported in people with weak immunity. Talk with your doctor before using this product if that applies to you.
What side effects should I watch for?
Most people have no issues, but some experience mild gastrointestinal symptoms like bloating, flatulence, abdominal discomfort, or diarrhea — especially when combining probiotics. Rarely, nausea, vomiting, or decreased appetite can occur with Saccharomyces boulardii.
Is it safe to take while pregnant?
Lactobacillus acidophilus and Bifidobacterium bifidum are rated possibly safe in pregnancy. We don't have pregnancy safety data on file for Saccharomyces boulardii or Bifidobacterium lactis, so talk with your doctor before taking this product during pregnancy.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if PureBi-Ome Intensive is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

PureBi-Ome Intensive label
Sources

Sources & How We Checked

PureBi-Ome Intensive's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 48 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Lactobacillus Acidophilus 15 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Begtrup LM, de Muckadell OB, Kjeldsen J, Christensen RD, Jarbøl DE. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol 2013;48(10):1127-35 PubMed
  3. Chatterjee S, Kar P, Das T, Ray S, Gangulyt S, Rajendiran C, Mitra M. Randomised placebo-controlled double blind multicentric trial on efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12 for prevention of antibiotic-associated
  4. Shavakhi A, Tabesh E, Yaghoutkar A, Hashemi H, Tabesh F, Khodadoostan M,Minakari M, Shavakhi S, Gholamrezaei A. The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-c
  5. Karamali M, Dadkhah F, Sadrkhanlou M, et al. Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Metab 2016;42(4):234-41. PubMed
  6. Badehnoosh B, Karamali M, Zarrati M, et al. The effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. J Matern Fetal Neonatal Med. 2018 May;31(9):1128-1136.
  7. Kumar S, Kumar R, Rohilla L, Jacob N, Yadav J, Sachdeva N. A high potency multi-strain probiotic improves glycemic control in children with new-onset type 1 diabetes mellitus: A randomized, double-blind, and placebo-controlled pilot study. Pediatr Diabete
  8. Shahriari A, Karimi E, Shahriari M, Aslani N, Khooshideh M, Arab A. The effect of probiotic supplementation on the risk of gestational diabetes mellitus among high-risk pregnant women: A parallel double-blind, randomized, placebo-controlled clinical trial PubMed
  9. Xiao SD, Zhang DZ, Lu H, et al. Multicenter, randomized, controlled trial of heat-killed Lactobacillus acidophilus LB in patients with chronic diarrhea. Adv Ther. 2003;20(5):253-60.
  10. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
  11. Ozer M, Goksu SY, Shahverdiani A, Mustafa M. Lactobacillus acidophilus-induced endocarditis and associated splenic abscess. Case Rep Infect Dis 2020;2020:1382709.
  12. Sadrin S, Sennoune S, Gout B, et al. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. Dig Liver Dis 2020;52(5):534-540. PubMed
  13. Stoffer JN, Slingsby TJ, Giuliari GP. Lactobacillus acidophilus endophthalmitis after intravitreal bevacizumab injection requiring intraocular lens explantation. Can J Ophthalmol 2022;57(1):e21-e22. PubMed
  14. Cukovic-Cavka S, Likic R, Francetic I, Rustemovic N, Opacic M, Vucelic B. Lactobacillus acidophilus as a cause of liver abscess in a NOD2/CARD15-positive patient with Crohn's disease. Digestion 2006;73(2-3):107-10.
  15. Hui J, Ren Y, Wang Y, Han Q. Lactobacillus acidophilus endophthalmitis postcataract operation: A case report with a literature review. Ocul Immunol Inflamm 2023.

See these in context on the Lactobacillus Acidophilus monograph →

Saccharomyces Boulardii 26 references
  1. Niault M, Thomas F, Prost J, et al. Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii. Clin Infect Dis 1999;28:930.
  2. Pletinex M, Legein J, Vandenplas Y. Fungemia with Saccharomyces boulardii in a 1-year-old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr 1995;21:113-5. DOI
  3. Fredenucci I, Chomarat M, Boucaud C, et al. Saccharomyces boulardii fungemia in a patient receiving ultra-levure therapy. Clin Infect Dis 1998;27:222-3.
  4. Elmer GW, McFarland LV, Surawicz CM, et al. Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 1999;13:1663-8.
  5. Lewis SJ, Freedman AR. Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther 1998;12:807-22. PubMed
  6. Cesaro S, Chinello P, Rossi L, Zanesco L. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer 2000;8:504-5. PubMed
  7. Hennequin C, Thierry A, Richard GF, et al. Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains. J Clin Microbiol 2001;39:551-9.
  8. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea - a pilot study. Z Gastroenterol 1993;31:129-34.
  9. Borriello SP, Hammes WP, Holzapfel W, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003;36:775-80. PubMed
  10. Marteau P, Seksik P. Tolerance of probiotics and prebiotics. J Clin Gastroenterol 2004;38:S67-9. PubMed
  11. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005;40:1625-34. PubMed
  12. Lherm, T., Monet, C., Nougiere, B., Soulier, M., Larbi, D., Le Gall, C., Caen, D., and Malbrunot, C. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002;28(6):797-801. PubMed
  13. Riquelme, A. J., Calvo, M. A., Guzman, A. M., Depix, M. S., Garcia, P., Perez, C., Arrese, M., and Labarca, J. A. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin.Gastroenterol. 2003;36(1):41- PubMed
  14. Cherifi, S., Robberecht, J., and Miendje, Y. Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis. Acta Clin Belg. 2004;59(4):223-224. PubMed
  15. Ellouze O, Berthoud V, Mervant M, Parthiot JP, Girard C. Septic shock due to Sacccaromyces boulardii. Med Mal Infect. 2016;46(2):104-105.
  16. Appel-da-Silva MC, Narvaez GA, Perez LRR, Drehmer L, Lewgoy J. Saccharomyces cerevisiae var. boulardii fungemia following probiotic treatment. Med Mycol Case Rep. 2017;18:15-7. PubMed
  17. Atici S, Soysal A, Karadeniz Cerit K, et al. Catheter-related Saccharomyces cerevisiae Fungemia Following Saccharomyces boulardii Probiotic Treatment: In a child in intensive care unit and review of the literature. Med Mycol Case Rep. 2017;15:33-35. PubMed
  18. Martin IW, Tonner R, Trivedi J, et al. Saccharomyces boulardii probiotic-associated fungemia: questioning the safety of this preventive probiotic's use. Diagn Microbiol Infect Dis. 2017;87(3):286-8. PubMed
  19. Romanio MR, Coraine LA, Maielo VP, Abramczyc ML, Souza RL, Oliveira NF. Saccharomyces cerevisiae fungemia in a pediatric patient after treatment with probiotics. Rev Paul Pediatr 2017;35(3):361-4.
  20. Roy U, Jessani LG, Rudramurthy SM, et al. Seven cases of Saccharomyces fungaemia related to use of probiotics. Mycoses 2017;60(6):375-380.
  21. Romanio MR, Coraine LA, Maielo VP, Abramczyc ML, Souza RL, Oliveira NF. Saccharomyces cerevisiae fungemia in a pediatric patient after treatment with probiotics. Rev Paul Pediatr. 2017 Jul-Sep;35(3):361-364. doi: 10.1590/1984-0462/;2017;35;3;00014.
  22. Flatley EA, Wilde AM, Nailor MD. Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile infection. J Gastrointestin Liver Dis. 2015;24(1):21-4. PubMed
  23. Ventoulis I, Sarmourli T, Amoiridou P, et al. Bloodstream infection by Saccharomyces cerevisiae in two COVID-19 patients after receiving supplementation of Saccharomyces in the ICU. J Fungi (Basel). 2020;6(3):98. PubMed
  24. Wombwell E, Bransteitter B, Gillen LR. Incidence of Saccharomyces cerevisiae fungemia in hospitalised patients administered Saccharomyces boulardii probiotic. Mycoses 2021;64(12):1521-1526.
  25. Rannikko J, Holmberg V, Karppelin M, et al. Fungemia and Other Fungal Infections Associated with Use of Saccharomyces boulardii Probiotic Supplements. Emerg Infect Dis 2021;27(8):2090-6.
  26. Awoyemi A, Mayerhofer C, Felix AS, et al. Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial. EBioMedicine 2021;70:103511. PubMed

See these in context on the Saccharomyces Boulardii monograph →

Bifidobacterium Bifidum 7 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74(2):336-42. PubMed
  3. Rerksuppaphol S, Rerksuppaphol L. Randomized controlled trial of probiotics to reduce common cold in schoolchildren. Pediatr Int. 2012;54(5):682-7. PubMed
  4. Karamali M, Dadkhah F, Sadrkhanlou M, et al. Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Metab 2016;42(4):234-41. PubMed
  5. Badehnoosh B, Karamali M, Zarrati M, et al. The effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. J Matern Fetal Neonatal Med. 2018 May;31(9):1128-1136.
  6. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  7. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7) PubMed

See these in context on the Bifidobacterium Bifidum monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring